Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.
Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback